Myriad Genetics, Inc. (MYGN): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem em rápida evolução da medicina de precisão, a Myriad Genetics, Inc. (MYGN) surge como uma força pioneira, transformando idéias genéticas em soluções de saúde que mudam a vida. Ao alavancar tecnologias de sequenciamento genético de ponta e serviços de diagnóstico abrangentes, a empresa está na vanguarda da avaliação de risco personalizada, oferecendo abordagens inovadoras para entender predisposições genéticas para condições críticas como o câncer. Seu modelo de negócios inovador integra pesquisas científicas avançadas, parcerias estratégicas e soluções centradas no paciente, criando um ecossistema exclusivo que capacita profissionais de saúde e indivíduos com conhecimento genético sem precedentes e estratégias médicas proativas.

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com profissionais de saúde e hospitais

A partir de 2024, a Miríade Genetics estabeleceu parcerias com as seguintes redes de assistência médica:

Parceiro de saúde	Foco em parceria	Ano estabelecido
Clínica Mayo	Colaboração de testes genéticos	2019
Memorial Sloan Kettering Cancer Center	Triagem genética oncológica	2020
Clínica de Cleveland	Avaliação de risco de câncer hereditário	2021

Parcerias de pesquisa com instituições de pesquisa acadêmica e médica

Miríade genética mantém colaborações de pesquisa ativa com as seguintes instituições:

• Universidade de Utah (parceiro de pesquisa primária)
• Departamento de Genética da Universidade de Stanford
• Johns Hopkins University School of Medicine
• Centro de Pesquisa de Genética da Escola de Medicina de Harvard

Empresas farmacêuticas para testes genéticos e desenvolvimento de medicamentos

Principais parcerias farmacêuticas a partir de 2024:

Empresa farmacêutica	Tipo de colaboração	Valor estimado da parceria
AstraZeneca	Teste de oncologia de precisão	US $ 45 milhões
Merck & Co.	Pesquisa genética de biomarcadores	US $ 38 milhões
Bristol Myers Squibb	Triagem genética do câncer	US $ 52 milhões

Companhias de seguros para cobertura e reembolso de testes genéticos

Parcerias de seguros para cobertura de testes genéticos:

• UnitedHealthcare
• Cruz azul do hino
• Cigna
• Aetna

Fabricantes de tecnologia e equipamentos de diagnóstico

Parcerias técnicas para equipamentos de diagnóstico:

Parceiro de tecnologia	Equipamento/tecnologia	Duração da parceria
Ilumina	Plataformas de sequenciamento de próxima geração	5 anos
Thermo Fisher Scientific	Instrumentos de análise genética	4 anos
Diagnóstico da Roche	Sistemas de diagnóstico molecular	6 anos

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: Atividades -chave

Testes genéticos e serviços de diagnóstico

Miríade genética realiza aproximadamente 250.000 testes genéticos anualmente. O portfólio de testes específico inclui:

Categoria de teste	Número de testes	Receita anual
Triagem hereditária de câncer	125,000	US $ 187,4 milhões
Testes de saúde reprodutiva	75,000	US $ 112,6 milhões
Testes genéticos de saúde mental	50,000	US $ 64,3 milhões

Pesquisa e Desenvolvimento Genético

Detalhes do investimento em pesquisa:

• Despesas anuais de P&D: US $ 98,7 milhões
• Número de projetos de pesquisa ativa: 42
• Portfólio de patentes: 276 patentes genéticas ativas

Medicina de precisão e triagem de oncologia

Especíadas de triagem de oncologia:

Tipo de triagem	Testes anuais	Penetração de mercado
Risco hereditário do câncer	95,000	67% do mercado -alvo
Perfil do tumor	45,000	52% dos centros de oncologia

Bioinformática e análise de dados

Recursos de processamento de dados:

• Dados genéticos processados ​​anualmente: 3.2 petabytes
• Algoritmos de aprendizado de máquina: 18 modelos proprietários
• Infraestrutura computacional: 672 servidores de computação de alto desempenho

Apoio aos ensaios clínicos e soluções de medicina personalizadas

Engajamento do ensaio clínico:

Categoria de teste	Ensaios ativos	Inscrição de participantes
Ensaios Oncológicos	23	4.750 participantes
Ensaios de saúde reprodutiva	12	2.300 participantes
Ensaios farmacogenômicos	7	1.100 participantes

Myriad Genetics, Inc. (Mygn) - Modelo de negócios: Recursos -chave

Tecnologias avançadas de sequenciamento genético

Miríade Genética utiliza plataformas de sequenciamento de próxima geração (NGS) com as seguintes especificações:

Tecnologia	Capacidade	Taxa de transferência
Illumina Novaseq 6000	Até 6 terabases por corrida	16 bilhões de leituras por corrida
Seqüenciador genético de torrente de íons	Sequenciamento de painel de genes direcionado	Até 50 milhões de leituras por corrida

Bancos de dados genéticos proprietários e algoritmos

Composição do banco de dados genético:

• Banco de dados de variantes genéticas totais: 3,8 milhões de variantes genéticas únicas
• Banco de dados de predisposição de câncer: 1,2 milhão de mutações genéticas relacionadas ao câncer anotadas
• Banco de dados de doenças hereditárias: mais de 500.000 marcadores genéticos clinicamente validados

Experiência em pesquisa científica

Composição da equipe de pesquisa e desenvolvimento:

Categoria	Número de profissionais
Pesquisadores de doutorado	87
Conselheiros genéticos	42
Especialistas em bioinformática	63

Infraestrutura de laboratório especializada

Detalhes das instalações de laboratório:

• Espaço total de laboratório: 78.000 pés quadrados
• Instalações certificadas pela CLIA: 3 centros de teste primários
• Capacidade de teste anual: 500.000 testes genéticos

Propriedade intelectual e portfólio de patentes

Categoria de patentes	Número de patentes	Faixa de validade
Métodos de teste genético	37	2025-2036
Algoritmos de diagnóstico	22	2027-2039
Identificação do marcador genético	15	2026-2033

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: proposições de valor

Detecção precoce de predisposições genéticas para doenças

Miríade Genética oferece testes genéticos com as seguintes métricas -chave:

Tipo de teste	Precisão da detecção	Volume anual de teste
Teste de câncer hereditário BRCA	99.3%	175.000 testes
Teste de risco de câncer de próstata	97.6%	85.000 testes

Avaliação de risco personalizada para câncer e condições hereditárias

Os serviços de avaliação de risco genético incluem:

• Triagem de câncer de mama e ovário hereditário
• Avaliação de risco genético do câncer colorretal
• Avaliação de risco genético para doenças cardiovasculares

Estratégias de tratamento do paciente aprimoradas

A abordagem de medicina de precisão da Miriad fornece:

Segmento de tratamento	Número de terapias direcionadas	Impacto do paciente
Oncologia Medicina de Precisão	42 terapias direcionadas	63.000 pacientes anualmente
Teste farmacogenômico	26 Interações com medicamentos	48.000 pacientes anualmente

Serviços abrangentes de triagem genética

O portfólio de triagem inclui:

• Triagem hereditária de câncer: 8 painéis genéticos diferentes
• Avaliação de risco genético pré -natal
• Diagnóstico genético de doenças raras

Insights avançados de diagnóstico para profissionais de saúde

Recursos de diagnóstico:

Categoria de diagnóstico	Número de marcadores genéticos	Taxa de utilidade clínica
Diagnóstico de oncologia	1.400+ marcadores genéticos	92% de utilidade clínica
Triagem de doenças hereditárias	1.100+ marcadores genéticos	88% de utilidade clínica

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: Relacionamentos do cliente

Consultas diretas com conselheiros genéticos

Miríade Genética fornece Serviços de aconselhamento genético 1 contra 1 com conselheiros profissionais em vários canais.

Tipo de consulta	Duração média	Volume anual
Consultas por telefone	45 minutos	12.500 sessões
Consultas em vídeo	60 minutos	8.750 sessões
Consultas pessoais	90 minutos	3.750 sessões

Portais de pacientes on -line e sistemas de suporte

Plataformas digitais que oferecem recursos abrangentes de envolvimento do paciente.

• Usuários ativos do portal Myrisk: 65.400
• Conformidade de privacidade de dados do paciente: HIPAA 100%
• Interações portais anuais: 425.000

Educação Médica Contínua

A Myriad fornece programas de treinamento especializados para profissionais de saúde.

Programa de Educação	Participantes anuais	Horário do programa
Treinamento genético oncológico	2.350 profissionais	12 horas
Aconselhamento genético reprodutivo	1.875 profissionais	8 horas

Comunicação de risco genético personalizado

Estratégias de Avaliação e Comunicação de Risco individualizadas.

• Relatórios de risco personalizados gerados: 87.500 anualmente
• Precisão da comunicação de risco: 98,3%
• Complexidade média do relatório: 12 marcadores genéticos

Interfaces de tecnologia em saúde digital

Plataformas tecnológicas avançadas para interação paciente e profissional.

Interface de tecnologia	Base de usuários	Interações anuais
Aplicativo móvel	42.600 usuários	315.000 interações
Portal da Web	93.500 usuários	625.000 interações

Myriad Genetics, Inc. (Mygn) - Modelo de negócios: Canais

Vendas diretas para profissionais de saúde

A miríade de genética utiliza uma força de vendas direta direcionada a oncologistas, ginecologistas e conselheiros genéticos. A partir de 2024, a empresa mantém uma equipe de vendas dedicada de 185 representantes de vendas diretas.

Canal de vendas	Número de representantes	Especialidades -alvo
Vendas de oncologia	95	Genética do câncer
Vendas de saúde da mulher	65	Saúde reprodutiva
Aconselhamento genético especializado	25	Testes genéticos complexos

Plataformas de teste genéticas online

A Myriad opera uma plataforma on -line abrangente para serviços de teste genético com o seguinte alcance digital:

• Usuários da plataforma digital: 412.000 usuários únicos em 2024
• Taxa de pedidos de teste on -line: 37% do total de testes genéticos
• Engajamento médio da plataforma digital: 22 minutos por sessão

Conferência Médica e Marketing de Rede Profissional

A empresa investe significativamente em marketing de rede profissional por meio de conferências médicas e eventos profissionais.

Canal de marketing	Investimento anual	Número de eventos
Conferências Médicas Nacionais	US $ 3,2 milhões	48 Conferências
Simpósios profissionais regionais	US $ 1,5 milhão	76 simpósios

Serviços de aconselhamento genético de telemedicina

Myriad oferece serviços de aconselhamento genético remoto com as seguintes métricas:

• Total de consultas de telemedicina em 2024: 24.700
• Duração média da consulta: 47 minutos
• Taxa de satisfação da plataforma de aconselhamento digital: 92%

Redes de provedores de seguros de saúde

Myriad mantém extensas parcerias com os provedores de seguros de saúde:

Rede de seguros	Porcentagem de cobertura	Taxa de reembolso
Fornecedores de seguros nacionais	87%	US $ 1.245 por teste genético
Redes de seguros regionais	63%	US $ 980 por teste genético

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: segmentos de clientes

Pacientes oncológicos e indivíduos com risco de câncer

A partir de 2024, a inúmeras genética tem como alvo aproximadamente 500.000 pacientes anuais de testes genéticos para o risco de câncer hereditário.

Segmento de pacientes	Volume de teste anual	Custo médio do teste
Risco de câncer de mama	250,000	$1,995
Risco de câncer de ovário	75,000	$2,250
Risco de câncer de próstata	100,000	$1,750
Risco de câncer de cólon	75,000	$1,500

Profissionais de saúde e médicos

Miríade genética atende a aproximadamente 85.000 prestadores de serviços de saúde ativos em todo o país.

• Oncologistas: 35.000 profissionais
• Profissionais da família: 25.000 profissionais
• Ginecologistas: 15.000 profissionais
• Urologistas: 10.000 profissionais

Centros de Aconselhamento Genético

A empresa suporta 2.300 centros de aconselhamento genético nos Estados Unidos.

Tipo central	Número de centros	Volume anual de referência
Hospitalado	750	45,000
Clínicas independentes	1,100	35,000
Centros Médicos Acadêmicos	450	20,000

Instituições de pesquisa

Miríade genética colabora com 650 instituições de pesquisa em todo o mundo.

• Centros de pesquisa acadêmica: 350
• Laboratórios de pesquisa farmacêutica: 180
• Instalações de pesquisa do governo: 120

Consumidores individuais que buscam idéias genéticas

O segmento de teste genético direto ao consumidor atinge aproximadamente 75.000 indivíduos anualmente.

Categoria de consumidor	Volume de teste anual	Preço médio de teste
Risco pessoal à saúde	45,000	$599
Análise de Ancestralidade e Traços	30,000	$399

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a inútil genética registrou despesas de P&D de US $ 135,4 milhões, representando 22,4% da receita total.

Ano fiscal	Despesas de P&D	Porcentagem de receita
2023	US $ 135,4 milhões	22.4%
2022	US $ 126,7 milhões	20.9%

Custos operacionais de laboratório

As despesas operacionais anuais do laboratório para inúmeras genética em 2023 totalizaram aproximadamente US $ 87,6 milhões.

• Custos de manutenção da instalação: US $ 22,3 milhões
• Depreciação do equipamento: US $ 18,5 milhões
• Suprimentos de laboratório: US $ 29,8 milhões
• Despesas de pessoal e pessoal: US $ 17 milhões

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de infraestrutura tecnológica para 2023 foram de US $ 43,2 milhões.

Componente de infraestrutura	Custo anual
Sistemas de TI	US $ 18,7 milhões
Computação em nuvem	US $ 12,5 milhões
Segurança cibernética	US $ 6,2 milhões
Licenciamento de software	US $ 5,8 milhões

Investimentos de ensaios clínicos

Os investimentos em ensaios clínicos para 2023 totalizaram US $ 64,9 milhões.

• Ensaios de oncologia: US $ 32,4 milhões
• Pesquisa de testes genéticos: US $ 21,5 milhões
• Estudos de doenças raras: US $ 11 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing para 2023 foram de US $ 92,3 milhões.

Canal de marketing	Despesas anuais
Equipe de vendas diretas	US $ 45,6 milhões
Marketing digital	US $ 22,7 milhões
Patrocínio de conferência e evento	US $ 14,2 milhões
Materiais promocionais	US $ 9,8 milhões

Myriad Genetics, Inc. (MYGN) - Modelo de negócios: fluxos de receita

Taxas de serviço de teste genético

Para o ano fiscal de 2023, a inúmera genética relatou taxas de serviço de teste genético, totalizando US $ 775,3 milhões. Os principais serviços de teste genético da empresa incluem:

• Teste de câncer hereditário
• Testes de saúde pré -natal e reprodutiva
• Teste genético de saúde mental

Categoria de teste	Receita (2023)
Teste de câncer hereditário	US $ 456,2 milhões
Teste pré -natal	US $ 218,7 milhões
Teste genético de saúde mental	US $ 100,4 milhões

Vendas de teste de diagnóstico

As vendas de testes de diagnóstico para inúmeras genética em 2023 atingiram US $ 632,1 milhões. O portfólio de diagnóstico da empresa inclui:

• Teste preciso de tumor
• Painéis de diagnóstico molecular
• Testes especializados de avaliação de risco genético

Categoria de teste de diagnóstico	Receita (2023)
Teste preciso de tumor	US $ 347,6 milhões
Painéis de diagnóstico molecular	US $ 184,5 milhões
Avaliação de risco genético	US $ 100,0 milhões

Colaborações de pesquisa farmacêutica

As receitas de colaboração de pesquisa farmacêutica para 2023 totalizaram US $ 87,5 milhões. Principais parcerias de pesquisa incluem colaborações com:

• Merck & Co.
• AstraZeneca
• Bristol Myers Squibb

Reembolsos de seguros

Os reembolsos de seguros para testes genéticos e de diagnóstico em 2023 totalizaram US $ 412,6 milhões. Redução de reembolso:

Categoria de seguro	Valor de reembolso (2023)
Seguro privado	US $ 276,4 milhões
Medicare	US $ 86,2 milhões
Medicaid	US $ 50,0 milhões

Serviços de consulta de medicina de precisão

Os serviços de consulta de medicina de precisão geraram US $ 55,2 milhões em receita para 2023. Os serviços incluem:

• Aconselhamento genético
• Recomendações de tratamento personalizadas
• Apoio à decisão clínica

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Value Propositions

You're looking at the core offerings Myriad Genetics, Inc. is putting forward to the market as of late 2025. These are the specific problems they solve for their customers-patients, providers, and pharma partners.

Comprehensive hereditary cancer risk assessment (MyRisk with RiskScore)

This offering focuses on assessing hereditary cancer risk across eleven cancer types, including breast, ovarian, and prostate. The RiskScore component adds a polygenic risk score layer to the traditional single-gene testing.

• MyRisk with RiskScore testing volume in oncology grew 14% year-over-year in the second quarter of 2025.
• Hereditary cancer testing revenue in Oncology grew 9% year-over-year in the second quarter of 2025.
• Hereditary cancer testing volume in Oncology grew 11% year-over-year in the third quarter of 2025.
• MyRisk affected test volume saw 11% year-over-year growth in the first quarter of 2025.
• Hereditary cancer testing revenue for the unaffected population increased 4% year-over-year in the third quarter of 2025.

Personalized psychotropic medication selection guidance (GeneSight)

GeneSight helps guide prescribing decisions for mental health medications based on a patient's genetic profile. This value proposition has faced recent headwinds, mainly from payer coverage changes.

• GeneSight test revenue was reported at $38.7 million for the third quarter of 2025.
• GeneSight test volume still managed to grow 8% year-over-year in the third quarter of 2025.
• Pharmacogenomics revenue saw a 20% fall in the first quarter of 2025, largely due to UnitedHealthcare discontinuing coverage.

Non-invasive prenatal screening and expanded carrier screening (Foresight, Prequel)

This area delivers insights for prenatal care, including expanded carrier screening. The Prequel test offers an early gestational age window for results.

• The Prequel test delivers critical insights at 8 week gestational age, compared to 10 to 12 weeks for other available tests.
• Prenatal testing revenue grew 7% year-over-year in the second quarter of 2025.
• In the first quarter of 2025, Foresight and Prequel prenatal tests achieved 15% revenue growth and 10% volume growth.

Prognostic information for prostate cancer treatment (Prolaris)

Prolaris provides prognostic information to help guide treatment decisions for prostate cancer patients, aligning with NCCN guidelines.

• Prolaris test revenue grew 4% year-over-year in the second quarter of 2025.
• Prolaris testing revenue grew 3% year-over-year in the third quarter of 2025.
• Revenue for Prolaris decreased 2% year-over-year in the first quarter of 2025.

Companion diagnostic (CDx) services for pharmaceutical clinical trials

Myriad Genetics, Inc. offers services to pharmaceutical partners to develop and provide CDx testing solutions, often involving liquid biopsy technology for therapy selection.

• In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic (CDx) testing solution.
• Existing CDx offerings include BRACAnalysis CDx and MyChoice CDx.

Here's a quick look at how the segments contributed to the overall financial picture as of the third quarter of 2025, which informed the raised full-year guidance.

Metric	Value (Latest Reported Period)	Period End Date
Total Revenue	$205.7 million	Q3 2025
Oncology Segment Revenue	$85.5 million	Q2 2025
Women's Health Segment Revenue	$89.8 million	Q2 2025
GeneSight Test Revenue	$38.7 million	Q3 2025
Adjusted Gross Margin	69.9%	Q3 2025
Adjusted EPS	$0.00	Q3 2025
FY 2025 Revenue Guidance (Raised Range)	$818 - $828 million	Full Year 2025

The company's ability to maintain a strong gross margin, reaching 71.2% in Q2 2025, shows operational discipline supporting these value propositions. Also, the adjusted EPS for Q2 2025 was $0.05, beating expectations.

The overall strategy is to accelerate growth by focusing on the Cancer Care Continuum, which directly supports the MyRisk and Prolaris value propositions. Finance: review the impact of the new $200 million term loan secured on July 31, 2025, on Q4 cash flow projections by next Tuesday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Customer Relationships

Myriad Genetics, Inc. maintains a high-touch engagement model with clinicians, supported by a substantial internal commercial structure. As of February 2025, the U.S. sales force was comprised of approximately 500 individuals across dedicated sales channels. The company is actively working to enhance its commercial capabilities and the overall customer digital experience to better serve the Cancer Care Continuum (CCC) market opportunity.

Digital integration is a key focus for streamlining clinician interaction. Myriad Genetics expects its full oncology portfolio of germline and tumor genomic tests to be fully integrated with both Flatiron's OncoEMR and Epic cloud-based platforms later in 2025. This integration is designed to create an end-to-end workflow solution allowing clinicians to order, receive, and review Myriad test results directly within their primary platforms. This deployment of electronic medical records (EMR) solutions was cited as a factor in the stable volume for hereditary cancer testing in the unaffected population during the first quarter of 2025.

Support for patients remains a component of the relationship strategy, explicitly including patient financial assistance programs. Furthermore, Myriad Genetics continues to engage with the genetic counseling community, presenting research at the National Society of Genetic Counselors (NSGC) 44th Annual Conference in November 2025, aiming to help make genetic testing more accessible for all patients.

Strategic, long-term relationships with Biopharma partners are leveraged to unlock new growth drivers, focusing on Biopharma service synergies. A significant development in late 2025 was the strategic collaboration entered into in September 2025 with SOPHiA GENETICS to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. Additionally, the company entered into an exclusive license agreement in February 2025 with PATHOMIQ to add its AI technology platform for prostate cancer, complementing the Prolaris Prostate Cancer Prognostic test.

Key metrics reflecting the scale and satisfaction within these customer relationships include:

• Net Promoter Score (NPS) consistently maintained above 70 since 2022.
• The company services over 45,000+ active ordering healthcare providers (data as of fourth quarter, 2023).
• The U.S. sales force size was approximately 500 individuals as of February 2025.

The following table summarizes key quantitative aspects related to Myriad Genetics, Inc.'s customer engagement as of recent 2025 reporting periods:

Relationship Metric Category	Specific Data Point	Reported Value (as of late 2025)
Clinician Reach	U.S. Dedicated Sales Force Size	Approximately 500 individuals
Digital Workflow	EMR Integration Target Platforms	Flatiron OncoEMR and Epic
Digital Workflow	EMR Full Integration Expectation	Later in 2025
Customer Satisfaction	Net Promoter Score (NPS)	Consistently above 70
Partnerships	New CDx Collaboration Announced	SOPHiA GENETICS (September 2025)
Partnerships	AI Technology License Agreement	PATHOMIQ (February 2025)

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Channels

You're looking at how Myriad Genetics, Inc. gets its molecular diagnostic tests into the hands of the clinicians and patients who need them. The channel strategy is a mix of traditional, high-touch sales and modern digital integration, which is key to navigating the complex reimbursement landscape.

The direct sales force remains a cornerstone. As of February 2025, this team comprised approximately 500 individuals in the U.S.. These representatives are focused on deep education and relationship building directly with ordering specialists. To support this, Myriad Genetics is actively investing in commercial capabilities; for instance, they are investing over $35 million in enhancing these channels and expanding the sales team as they head into 2026.

Integration with the provider workflow is another major channel focus. Myriad Genetics is expanding its footprint in Electronic Medical Records (EMR) systems across hospital systems and large clinic networks. This is designed to make ordering and reporting seamless right where the doctor works. You can see this effort reflected in the Women's Health segment; in the second quarter of 2025, hereditary cancer testing volume for the unaffected population grew by 3% year-over-year, partly due to expanding these EMR solutions.

Here's a snapshot of the scale of these channel relationships as of the latest data:

Channel Metric	Value/Amount	Context/Date
U.S. Direct Sales Force Size	Approximately 500 individuals	As of February 2025
Total Payer Contracts	Over 3000	Reported
Testing Volume Covered by Insurance	Approximately 90%	In 2024
Investment in Commercial Channel Expansion	Over $35 million	Planned for 2026 growth
GeneSight Revenue (Q3 2025)	$38.7 million	Reflecting payer coverage headwinds

Navigating third-party payors is critical for access and revenue. Myriad Genetics maintains contracts with over 3000 payers, which is how they secure broad test coverage. However, this channel faces immediate risk; the discontinuation of coverage for the GeneSight test by UnitedHealthcare, effective in the first quarter of 2025, created a significant headwind. Still, other areas show payer progress; prenatal testing revenue in the second quarter of 2025 grew by 7% year-over-year, driven by expanding payer coverage for the Foresight Expanded Carrier Screen.

For certain tests, Myriad Genetics uses direct-to-patient marketing to build awareness and drive provider orders. This is a growing area, as they are increasing digital marketing efforts. However, this approach shows mixed results depending on the product. For example, in the third quarter of 2025, prenatal volume decreased by 3% year-over-year, largely driven by lower demand for the SneakPeek test. The company is definitely working to optimize this direct outreach.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Customer Segments

The customer segments for Myriad Genetics, Inc. are clearly delineated across clinical specialties, each served by specific diagnostic offerings.

Oncology: Physicians and patients with cancer or high-risk for hereditary cancer

This segment is served by hereditary cancer testing, including the MyRisk Hereditary Cancer Test, and companion diagnostic tests like BRACAnalysis CDx and MyChoice CDx.

The performance metrics for the Oncology segment show growth in testing volume:

Metric	Period Ended Q2 2025	Period Ended Q3 2025
Revenue	$85.5 million	$81.8 million
Hereditary Cancer Testing Volume Growth (YoY)	10%	11%
MyRisk with RiskScore Testing Volume Growth (YoY)	14%	13%

The Prolaris Prostate Cancer Prognostic Test also targets this group:

• Prolaris test revenue grew 4% year-over-year in the second quarter of 2025.
• Prolaris testing revenue grew 3% year-over-year in the third quarter of 2025.

Myriad Genetics plans to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first quarter of 2026.

Women's Health: OB/GYNs, maternal-fetal medicine specialists, and pregnant patients

This segment focuses on prenatal and carrier screening tests, including Foresight Carrier Screen and Prequel Prenatal Screen.

Revenue performance for Women's Health:

Metric	Period Ended Q1 2025	Period Ended Q2 2025
Prenatal Testing Revenue	$55 million	$89.8 million (Segment Revenue)
Prenatal Testing Revenue Growth (YoY)	11%	7%
Prenatal Volume Change (YoY)	Not specified	Decreased 8% (Q2 2025 total prenatal volume vs prior year)

The third quarter of 2025 showed Prenatal testing revenue growth of 2% year-over-year, with volume decreasing 3% year-over-year.

The company launched the Prequel®Early Gestational Age test in the mid-fourth quarter of 2024, showing positive early adoption in the first quarter of 2025.

Mental Health: Psychiatrists and primary care physicians prescribing psychotropics

The primary offering for this segment is the GeneSight test for pharmacogenomics.

This segment faced significant headwinds:

• First quarter 2025 Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare reducing coverage of GeneSight.
• GeneSight test revenue was $37.8 million in the second quarter of 2025.
• Pharmacogenomics revenue decreased by $5.2 million in Q2 2025 due to a 16% decrease in average revenue per test, impacted by the UnitedHealthcare coverage change.
• GeneSight test volume in the second quarter of 2025 grew 5% year-over-year.

Pharmaceutical and Biopharma companies for CDx development services

Myriad Genetics, Inc. supports Biopharma partners with companion diagnostic (CDx) development and customized clinical trial testing.

The company has supported hundreds of clinical trials.

In September 2025, Myriad Genetics entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

The company expects to leverage strategic partnerships and Biopharma service synergies to unlock new growth drivers.

Myriad Genetics operates in the Global Companion Diagnostics Market, which was valued at USD $7.2 billion in 2024.

The company serves more than 51,000 physicians across its specialties as of August 2025.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the ledger for Myriad Genetics, Inc. (MYGN) as of late 2025. It's a mix of direct lab costs, heavy commercial spend, and managing a new debt load. Honestly, for a diagnostics company, the cost structure is dominated by the lab work and getting those tests into the hands of clinicians.

The direct costs tied to running the tests, which we call Cost of Revenue, were reported at $61.9 million for the third quarter of 2025. This figure is key because it directly drives the gross margin, which management noted was a strong 69.9% for that same quarter. That margin tells you the core science and lab process is efficient, which is definitely a positive sign.

When we look at the operating expenses, the commercial engine is clearly the biggest driver. Sales and Marketing expenses represented 34.5% of the total Q3 2025 revenue of $205.7 million. Also, Research and Development (R&D) investment, which fuels future growth pipelines like the planned AI-enabled prostate cancer test launch in 2026, consumed 13.7% of that revenue base.

To give you a clearer picture of the operating spend, here is how the major components stack up for Q3 2025. We can see that the specified costs align almost exactly with the reported total operating expenses.

Expense Category	Reported Value/Percentage (Q3 2025)	Calculated Dollar Amount (Approx.)
Cost of Revenue	$61.9 million	$61.9 million
Sales and Marketing (as % of Revenue)	34.5%	Approx. $71.0 million
Research and Development (as % of Revenue)	13.7%	Approx. $28.2 million
General and Administrative (G&A)	$67.9 million	$67.9 million
Total Specified Operating Costs	N/A	Approx. $167.1 million
Total Reported Operating Expenses	$167.1 million	$167.1 million

The General and Administrative (G&A) costs were a fixed-looking $67.9 million in the quarter. It's important to note that management has been focused on disciplined cost management, as the total operating expenses of $167.1 million actually decreased year-over-year by $2.7 million. That discipline helps push the adjusted EBITDA to a positive $10.3 million, even with the heavy commercial spend.

Finally, you can't ignore the balance sheet costs impacting cash flow. Myriad Genetics entered a new $200 million term loan facility in July 2025. Servicing this debt is a fixed commitment that needs to be factored into ongoing cash planning, separate from the operational P&L line items. You have to account for the interest and principal payments on that facility moving forward.

Here are the key cost drivers you need to keep an eye on:

• Cost of Revenue: $61.9 million in Q3 2025.
• Sales and Marketing: Accounted for 34.5% of revenue.
• R&D Investment: Took up 13.7% of revenue.
• G&A Overhead: A flat $67.9 million for the quarter.
• New Debt Obligation: Servicing the $200 million term loan.

Finance: draft 13-week cash view by Friday.

Myriad Genetics, Inc. (MYGN) - Canvas Business Model: Revenue Streams

You're looking at how Myriad Genetics, Inc. (MYGN) brings in the cash, which is all about the tests they sell. For the full fiscal year 2025, the company reaffirmed its revenue guidance to be in the range of $818 million - $828 million. That guidance was reiterated following solid execution in the third quarter of 2025, even though consolidated revenue for that quarter was reported at $205.7 million, a 4% decrease year-over-year, but flat when excluding certain headwinds.

The revenue streams are clearly segmented by their primary diagnostic areas. Hereditary Cancer testing, driven by MyRisk, remains a cornerstone, but you see significant contributions from Prenatal and Pharmacogenomics as well. Honestly, the mix shows a strategic focus on the Cancer Care Continuum, but Women's Health and Mental Health still provide substantial top-line support. It's all about getting tests ordered and paid for.

Here's a look at the revenue generated by the key testing categories for the third quarter of 2025:

• Hereditary Cancer testing (MyRisk) brought in $93.0 million.
• Prenatal testing (Foresight, Prequel) generated $44.5 million.
• Pharmacogenomics testing (GeneSight) accounted for $38.7 million.
• Tumor Profiling (Prolaris, myChoice CDx) contributed $29.5 million.

The growth story is often in the volume, not just the dollars. For instance, hereditary cancer testing volume in Oncology grew 9% year-over-year in Q3 2025, and GeneSight test volume was up 8% year-over-year. Still, average revenue per test across the board saw a 7% drop in Q3 2025, which pressures the top line even when volumes are up.

To map out the key revenue drivers from the third quarter of fiscal 2025, this table breaks down the reported segment contributions:

Revenue Stream Category	Product Focus	Q3 2025 Revenue Amount
Hereditary Cancer Testing (Oncology Focus)	MyRisk (Oncology)	$93.0 million
Women's Health Testing	Hereditary Cancer (Unaffected Population)	$44.5 million
Pharmacogenomics	GeneSight	$38.7 million
Tumor Profiling	Prolaris, myChoice CDx	$29.5 million

You can see the Women's Health business, which includes prenatal and hereditary cancer testing for the unaffected population, delivered total revenue of $85.2 million in Q3 2025. The Oncology business, focused on hereditary cancer and Prolaris, brought in $81.8 million in the same period. The difference between the sum of the four listed streams and the total revenue reflects other smaller streams, like Mental Health revenue (which includes GeneSight) and any revenue from divested assets or partnerships not explicitly broken out in the prompt's required list. Finance: draft 13-week cash view by Friday.